Clinical trials: Hypothalamic-pituitary Disorders
Acromegaly
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
This is a phase IIIb multicenter, open-label; single arm study to evaluate the efficacy and safety of pasireotide LAR 40 mg and 60 mg in patients with inadequately controlled acromegaly with maximal approved doses of first…
- Trial name
- NCT02354508
- Testing
- Pasireotide LAR
- Where
- 50 sites in Argentina, Belgium and 13 more
- Volunteers
- 123 people
- Sponsor
- Novartis Pharmaceuticals
Affective Disorders, Psychotic, Depressive Disorder
Treatment of Psychotic Major Depression With Mifepristone
The purpose of this research study is to see how certain hormones cause changes in mood and thinking in some depressed patients and to determine the effectiveness of mifepristone in treating some forms of depression.
- Trial name
- NCT00867360
- Testing
- Mifepristone (RU-486)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University
Acromegaly, Neuroendocrine Tumors
Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)
This is a Phase II, open-label multicentre, randomised study to assess the PK, PD, efficacy, and safety of two dosing regimens of CAM2029 in adult patients with acromegaly or a functional, well-differentiated NET, with carcinoid…
- Trial name
- NCT02299089
- Testing
- octreotide FluidCrystal® injection depot
- Where
- 10 sites in France, Germany and 2 more
- Volunteers
- 12 people
- Sponsor
- Camurus AB
Acromegaly
A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly
The purpose of this study was to determine the safety, tolerability, and efficacy of IONIS-GHR-LRx subcutaneous (SC) injection as monotherapy in patients with acromegaly.
- Trial name
- NCT04522180
- Testing
- GHR-LRX
- Where
- 22 sites in United States, Estonia and 8 more
- Volunteers
- 34 people
- Sponsor
- Ionis Pharmaceuticals, Inc.